Lexaria Bioscience Expected to Post 9-Cent Loss, Revenue Plunge 71% Amid Going Concern Doubts
LEXX has more than doubled off its 52-week low of $0.46.
Summary
Lexaria Bioscience Corp. is expected to report a significant loss of 9 cents per share and a 71.3% year-over-year revenue decrease to just $50,000 for the quarter ending February 28, 2026. This earnings preview reinforces the company's precarious financial position, especially given its prior disclosure of substantial doubt about its ability to continue as a going concern and recent dilutive offerings. For a micro-cap company, such a drastic decline in revenue and continued losses are highly material and signal ongoing operational challenges. Traders will be closely watching the actual results, expected around April 13, for confirmation of these negative trends and any further updates on its financial viability.
At the time of this announcement, LEXX was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.5M. The 52-week trading range was $0.46 to $1.69. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.